Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 in intermediate trophoblastic tumors
ChiCTR2500101129Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of QL1706, iparomlimab and tuvorlimab in intermediate trophoblastic tumor, placental site trophoblastic tumor (PSTT) and epithelioid trophoblastic tumor (ETT) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Complete response rate. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
QL1706iparomlimabtuvorlimab
03
Conditions
intermediate trophoblastic tumorplacental site trophoblastic tumor (PSTT)epithelioid trophoblastic tumor (ETT)
Beyond the preview
Go deeper on ChiCTR2500101129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101129.